|
1
|
Yang JD and Roberts LR: Hepatocellular
carcinoma: A global view. Nat Rev Gastroenterol Hepatol. 7:448–458.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Nerenstone SR, Ihde DC and Friedman MA:
Clinical trials in primary hepatocellular carcinoma: current status
and future directions. Cancer Treat Rev. 15:1–31. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mathurin P, Rixe O, Carbonell N, Bernard
B, Cluzel P, Bellin MF, Khayat D, Opolon P and Poynard T: Review
article: Overview of medical treatments in unresectable
hepatocellular carcinoma - an impossible meta-analysis? (Review)
Aliment Pharmacol Ther. 12:111–126. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Llovet JM, Burroughs A and Bruix J:
Hepatocellular carcinoma. Lancet. 362:1907–1917. 2003. View Article : Google Scholar
|
|
5
|
Kawano Y, Sasaki A, Kai S, Endo Y, Iwaki
K, Uchida H, Shibata K, Ohta M and Kitano S: Prognosis of patients
with intrahepatic recurrence after hepatic resection for
hepatocellular carcinoma: a retrospective study. Eur J Surg Oncol.
35:174–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamamoto M, Sato S, Hemmi H, Hoshino K,
Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K and
Akira S: Role of adaptor TRIF in the MyD88-independent toll-like
receptor signaling pathway. Science. 301:640–643. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alexopoulou L, Holt AC, Medzhitov R and
Flavell RA: Recognition of double-stranded RNA and activation of
NFkappaB by Toll-like receptor 3. Nature. 413:732–738. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Heylbroeck C, Balachandran S, Servant MJ,
DeLuca C, Barber GN, Lin R and Hiscott J: The IRF-3 transcription
factor mediates Sendai virus-induced apoptosis. J Virol.
74:3781–3792. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Salaun B, Coste I, Rissoan MC, Lebecque SJ
and Renno T: TLR3 can directly trigger apoptosis in human cancer
cells. J Immunol. 176:4894–4901. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Salaun B, Lebecque S, Matikainen S,
Rimoldi D and Romero P: Toll-like receptor 3 expressed by melanoma
cells as a target for therapy? Clin Cancer Res. 13:4565–4574. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qun E, Li Chen, Jin Guo Hua, et al:
portfolio tool of paraffin tissue microarray[Z]. CN201402229.
Nantong university; 2010
|
|
12
|
Qun E, Li Chen and Qiu Kai E: preparation
methods of paraffin tissue microarray[Z]. CN101319971. Nantong
university; 2008
|
|
13
|
Khvalevsky E, Rivkin L, Rachmilewitz J,
Galun E and Giladi H: TLR3 signaling in a hepatoma cell line is
skewed towards apoptosis. J Cell Biochem. 100:1301–1312. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chua CW and Choo SP: Targeted therapy in
hepatocellular carcinoma. Int J Hepatol. 2011:3482972011.PubMed/NCBI
|
|
15
|
Bergé M, Bonnin P, Sulpice E, Vilar J,
Allanic D, Silvestre JS, Lévy BI, Tucker GC, Tobelem G and
Merkulova-Rainon T: Small interfering RNAs induce
target-independent inhibition of tumor growth and vasculature
remodeling in a mouse model of hepatocellular carcinoma. Am J
Pathol. 177:3192–3201. 2010.PubMed/NCBI
|
|
16
|
Zorde-Khvalevsky E, Abramovitch R, Barash
H, Spivak-Pohis I, Rivkin L, Rachmilewitz J, Galun E and Giladi H:
Toll-like receptor 3 signaling attenuates liver regeneration.
Hepatology. 50:198–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ferreon JC, Ferreon AC, Li K and Lemon SM:
Molecular determinants of TRIF proteolysis mediated by the
hepatitis C virus NS3/4A protease. J Biol Chem. 280:20483–20492.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kleinman ME, Yamada K, Takeda A,
Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJ, Yamasaki S,
Itaya M, Pan Y, et al: Sequence- and target-independent
angiogenesis suppression by siRNA via TLR3. Nature. 452:591–597.
2008. View Article : Google Scholar : PubMed/NCBI
|
